Unlocking the potential of approved drugs for the allosteric inhibition of tropomyosin-receptor kinase A using molecular docking and molecular dynamics studies

Tropomyosin-receptor kinase A (TrkA) is the primary isoform among the tropomyosin-receptor kinases that have been associated with human cancer development, contributing to approximately 7.4% of all cancer cases. TrkA represents an attractive target for cancer treatment; however, currently available...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukhtar, Rua M., Abdelmoniem, Nihal, Elrufaie, Hisham A., Edris, Alaa, Ghaboosh, Hiba, Mahgoub, Mohanad A., Garelnabi, Elrashied A. E., Osman, Wadah, Sherif, Asmaa E., Ashour, Ahmed, Ghazawi, Kholoud F., Samman, Waad A., Alhaddad, Aisha A., Bafail, Rawan, Ibrahim, Sabrin R. M., Mohamed, Gamal A., Alzain, Abdulrahim A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282146/
https://www.ncbi.nlm.nih.gov/pubmed/37351516
http://dx.doi.org/10.3389/fchem.2023.1205724

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282146/
https://www.ncbi.nlm.nih.gov/pubmed/37351516
http://dx.doi.org/10.3389/fchem.2023.1205724

Ejemplares similares